ArticleCancer science2022

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

Dai Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.